Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
| Status: | Completed |
|---|---|
| Conditions: | Other Indications, Overactive Bladder, Neurology, Urology, Multiple Sclerosis |
| Therapuetic Areas: | Gastroenterology, Nephrology / Urology, Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/14/2017 |
| Start Date: | June 2012 |
| End Date: | March 2015 |
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the
treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
Inclusion Criteria:
- At least 3 episodes of urinary incontinence over a 3-day period
- History of Multiple Sclerosis (MS)
- Urinary incontinence not adequately controlled by anticholinergic medication
Exclusion Criteria:
- Current use of intermittent catheter or indwelling catheter to manage urinary
incontinence
- Previous or current botulinum toxin therapy of any serotype for any urological
condition
- Previous or current botulinum toxin therapy of any serotype for any non-urological
condition within the last 12 weeks
- Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, or Amyotrophic Lateral
Sclerosis
We found this trial at
2
sites
Click here to add this to my saved trials
